Notice: This company has been marked as potentially delisted and may not be actively trading. Reliv' International (RELV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends RELV vs. NXTC, TENX, LSB, BIVI, LSTA, NNVC, CMMB, LPCN, GLYC, and CARMShould you be buying Reliv' International stock or one of its competitors? The main competitors of Reliv' International include NextCure (NXTC), Tenax Therapeutics (TENX), Lakeshore Biopharma (LSB), BioVie (BIVI), Lisata Therapeutics (LSTA), NanoViricides (NNVC), Chemomab Therapeutics (CMMB), Lipocine (LPCN), GlycoMimetics (GLYC), and Carisma Therapeutics (CARM). Reliv' International vs. NextCure Tenax Therapeutics Lakeshore Biopharma BioVie Lisata Therapeutics NanoViricides Chemomab Therapeutics Lipocine GlycoMimetics Carisma Therapeutics Reliv' International (NASDAQ:RELV) and NextCure (NASDAQ:NXTC) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has preferable earnings & valuation, RELV or NXTC? Reliv' International has higher revenue and earnings than NextCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReliv' International$35.06M0.15-$440KN/AN/ANextCureN/AN/A-$62.72M-$1.98-0.36 Do insiders & institutionals have more ownership in RELV or NXTC? 8.0% of Reliv' International shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 31.2% of Reliv' International shares are held by insiders. Comparatively, 13.3% of NextCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in RELV or NXTC? Reliv' International received 23 more outperform votes than NextCure when rated by MarketBeat users. Likewise, 70.27% of users gave Reliv' International an outperform vote while only 64.80% of users gave NextCure an outperform vote. CompanyUnderperformOutperformReliv' InternationalOutperform Votes10470.27% Underperform Votes4429.73% NextCureOutperform Votes8164.80% Underperform Votes4435.20% Does the media favor RELV or NXTC? In the previous week, NextCure had 9 more articles in the media than Reliv' International. MarketBeat recorded 9 mentions for NextCure and 0 mentions for Reliv' International. NextCure's average media sentiment score of 0.41 beat Reliv' International's score of 0.00 indicating that NextCure is being referred to more favorably in the news media. Company Overall Sentiment Reliv' International Neutral NextCure Neutral Do analysts recommend RELV or NXTC? NextCure has a consensus price target of $3.50, indicating a potential upside of 386.11%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Reliv' International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reliv' International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, RELV or NXTC? Reliv' International has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Is RELV or NXTC more profitable? NextCure has a net margin of 0.00% compared to Reliv' International's net margin of -0.61%. Reliv' International's return on equity of -1.89% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets Reliv' International-0.61% -1.89% -1.31% NextCure N/A -62.50%-53.67% SummaryNextCure beats Reliv' International on 9 of the 16 factors compared between the two stocks. Remove Ads Get Reliv' International News Delivered to You Automatically Sign up to receive the latest news and ratings for RELV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RELV vs. The Competition Export to ExcelMetricReliv' InternationalPharmaceutical Preparations IndustryStaples SectorNASDAQ ExchangeMarket Cap$5.17M$6.93B$16.83B$7.93BDividend YieldN/A2.72%2.80%4.05%P/E Ratio-26.916.1115.9518.73Price / Sales0.15219.832.43119.11Price / Cash44.5365.6716.3934.64Price / Book0.476.616.694.19Net Income-$440,000.00$139.99M$737.95M$247.07M Reliv' International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RELVReliv' InternationalN/A$2.96flatN/AN/A$5.17M$35.06M-26.9191NXTCNextCure4.2652 of 5 stars$0.74-2.0%$3.50+376.1%-52.8%$20.59MN/A-0.3590Earnings ReportUpcoming EarningsAnalyst RevisionTENXTenax Therapeutics1.9747 of 5 stars$6.02-2.7%$18.00+199.0%+60.0%$20.52MN/A0.009Analyst ForecastAnalyst RevisionNews CoverageLSBLakeshore Biopharma1.5086 of 5 stars$2.02-6.9%N/AN/A$20.22M$672.27M0.00773Short Interest ↓Gap DownBIVIBioVie2.2485 of 5 stars$1.09-8.4%$3.00+175.2%+58.5%$20.11MN/A-0.1110LSTALisata Therapeutics2.323 of 5 stars$2.33-1.3%$15.00+543.8%-27.1%$20.09M$1M-0.9330Short Interest ↑Gap UpNNVCNanoViricidesN/A$1.16-8.7%N/A+6.0%$18.14MN/A-1.6120CMMBChemomab Therapeutics2.9175 of 5 stars$1.30+4.0%$9.00+592.3%+65.1%$17.95MN/A-1.3020Short Interest ↑Gap DownLPCNLipocine2.1157 of 5 stars$3.20-7.0%$10.00+212.5%-18.9%$17.11M$7.92M-4.2110Earnings ReportNews CoverageGap DownGLYCGlycoMimetics3.7211 of 5 stars$0.26-4.2%$8.00+2,965.1%-90.1%$16.84M$10,000.000.0050Short Interest ↑Gap DownCARMCarisma Therapeutics3.3768 of 5 stars$0.40-10.8%$4.94+1,135.0%-82.8%$16.70M$20.27M-0.2620Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies NXTC Competitors TENX Competitors LSB Competitors BIVI Competitors LSTA Competitors NNVC Competitors CMMB Competitors LPCN Competitors GLYC Competitors CARM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RELV) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reliv' International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reliv' International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
